文献速递造血干细胞移植与细胞治疗

单倍体造血干细胞移植后环磷酰胺方案下NK细胞恢复的动态变化及其临床意义

NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications.
PubMed 文献 · Blood · 2017-10-06

本研究在2个独立中心对17例接受未处理单倍体移植并采用移植后环磷酰胺(PT-Cy)方案的患者进行NK细胞动态分析,发现PT-Cy输注后增殖性NK细胞显著减少,成熟NK细胞被清除,而第15天后未成熟NK细胞(CD62L+NKG2A+KIR-)占优势;在99例扩展队列中,预测NK同种反应性与否对1年无进展生存率无显著差异(42% vs 52%,P=NS)。

要点

  • PT-Cy输注后增殖性NK细胞显著减少,提示选择性清除分裂中的细胞。
  • PT-Cy清除成熟NK细胞后,第15天起未成熟NK细胞(CD62L+NKG2A+KIR-)高度富集。
  • 99例PT-Cy单倍体移植中,预测NK同种反应性与否对1年无进展生存率无显著差异(42% vs 52%,P=NS)。

核心结论

  • 大部分未处理移植物中的成熟NK细胞在PT-Cy给药后被清除,削弱了该移植环境下的NK细胞同种反应性。

研究设计与样本

  • 研究在2个独立中心对17例接受未处理单倍体移植并采用PT-Cy方案的患者进行NK细胞动态分析,另在99例PT-Cy单倍体移植扩展队列中分析无进展生存。

主要发现

  • 两个系列均观察到供者来源NK细胞在HSCT后立即出现强劲增殖。
  • PT-Cy输注后增殖性NK细胞显著减少,且增殖性NK细胞不表达乙醛脱氢酶,体外可被Cy杀死。
  • HSCT后第15天起,在患者血清中高水平的白细胞介素-15支持下,未成熟NK细胞(CD62L+NKG2A+KIR-)高度富集,可能直接来源于输注的造血干细胞。
  • 推测的同种反应性单个KIR+NK细胞也被PT-Cy清除,导致HSCT后第30天其数量及抗白血病潜力下降。
  • 在99例PT-Cy单倍体移植扩展队列中,预测有或无NK同种反应性的患者1年无进展生存率分别为42%和52%,无显著差异(P=NS)。

关键数值与推荐

  • 在99例PT-Cy单倍体移植患者中,预测有NK同种反应性者1年无进展生存率为42%,无预测NK同种反应性者为52%,差异无统计学意义(P=NS)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of posttransplant cyclophosphamide (PT-Cy) as graft-versus-host disease (GVHD) prophylaxis has revolutionized haploidentical hematopoietic stem cell transplantation (HSCT), allowing safe infusion of unmanipulated T cell-replete grafts. PT-Cy selectively eliminates proliferating alloreactive T cells, but whether and how it affects natural killer (NK) cells and their alloreactivity is largely unknown. Here we characterized NK cell dynamics in 17 patients who received unmanipulated haploidentical grafts, containing high numbers of mature NK cells, according to PT-Cy-based protocols in 2 independent centers. In both series, we documented robust proliferation of donor-derived NK cells immediately after HSCT. After infusion of Cy, a marked reduction of proliferating NK cells was evident, suggesting selective purging of dividing cells. Supporting this hypothesis, proliferating NK cells did not express aldehyde dehydrogenase and were killed by Cy in vitro. After ablation of mature NK cells, starting from day 15 after HSCT and favored by the high levels of interleukin-15 present in patients' sera, immature NK cells (CD62L+NKG2A+KIR-) became highly prevalent, possibly directly stemming from infused hematopoietic stem cells. Importantly, also putatively alloreactive single KIR+ NK cells were eliminated by PT-Cy and were thus decreased in numbers and antileukemic potential at day 30 after HSCT. As a consequence, in an extended series of 99 haplo-HSCT with PT-Cy, we found no significant difference in progression-free survival between patients with or without predicted NK alloreactivity (42% vs 52% at 1 year, P = NS). Our data suggest that the majority of mature NK cells infused with unmanipulated grafts are lost upon PT-Cy administration, blunting NK cell alloreactivity in this transplantation setting.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Russo A, Oliveira G, Berglund S, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2017. PMID: 28986344. doi:10.1182/blood-2017-05-780668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。